Century Therapeutics, Inc. (IPSC) vs Prelude Therapeutics Incorporated (PRLD)

Century Therapeutics, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Century Therapeutics, Inc. and Prelude Therapeutics Incorporated are of similar size ($318.4M and $306.0M). Century Therapeutics, Inc. has the higher net margin (0.00% vs −269.8%) and the lower return on invested capital (−64.9% vs 0.00%). Across the 14 metrics below, Century Therapeutics, Inc. leads on 10 and Prelude Therapeutics Incorporated on 4.

Valuation

Metric IPSC PRLD Biotechnology median
P/E n/m n/m 7.88
P/S 2.99 17.02 11.47
P/B 1.48 2.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.95 10.26 10.73
Earnings yield (55.69%) (18.81%) (28.84%)
Free cash flow yield (25.62%) (8.73%) (23.03%)

Profitability

Metric IPSC PRLD Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (300.56%) 0.00%
Net margin 0.00% (269.75%) 0.00%
Free cash flow margin 0.00% (148.30%) 0.00%
Return on equity (49.65%) (57.73%) (57.72%)
Return on assets (38.41%) (39.76%) (49.22%)
Return on invested capital (64.92%) 0.00% 0.00%

Growth

Metric IPSC PRLD Biotechnology median
Revenue growth (TTM) 8,286.72% — 5.64%
EPS growth (last fiscal year) 93.12% 23.21% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IPSC PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.28 4.07 4.73
Net debt to EBITDA 17.95 1.00 0.96

Dividend

Metric IPSC PRLD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IPSC PRLD Biotechnology median
Market cap 306.02m 318.42m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack